Fresenius

Investor News

Nick Stone
Senior Vice President
Investor Relations

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
nick.stone@fresenius.com
www.fresenius.com

September 25, 2026

Fresenius expands European production capacity to enhance healthcare supply chain resilience

- Opening of new I.V. product lines in Kutno, Poland and Isola della Scala, Italy
- Combined investments of €54 million; more than €1 billion invested in European manufacturing over the past five years
- Fresenius further advances local-for-local approach and commitment to European patient care

Bad Homburg, Germany, September 25, 2026 – Fresenius is strengthening its European manufacturing network with new and expanded production capabilities for intravenous (IV) fluids in Poland and Italy. This week, the company opened a new IV fluids production line in Kutno, Poland, and expanded its manufacturing and warehouse infrastructure in Isola della Scala, Italy. Both sites play an important role in supplying European healthcare systems with essential medicines, helping ensure access for hospitals and patients across the region. Together representing investments of €54 million, the projects increase local production capacity, reinforce healthcare supply chains, and strengthen the availability of essential healthcare products across Europe.

Over the past five years, Fresenius has invested more than €1 billion in European production to enhance resilience and support healthcare systems. As a global healthcare company, Fresenius manufactures many of its products close to the patients it serves. The company operates around 20 manufacturing facilities and several research and development centers across Europe.

Healthcare systems face growing demand, increasing complexity, and rising expectations for reliable access. Through the continuous expansion and modernization of its manufacturing network, Fresenius is helping improve the availability of critical medicines, clinical nutrition products, and medical technologies for patients.

"Europe needs strong healthcare systems supported by resilient local manufacturing. With our investments in Poland and Italy, we are bringing essential production closer to patients and advancing our local-for-local approach, while at the same time strengthening security of supply. Healthcare is part of Europe's security architecture, and resilient value chains are essential for greater sovereignty. This is #FutureFresenius in action: focused investments that create value for patients, customers and our businesses."
Dr. Marc-Alexander Mahl, President Pharma, Medical Nutrition & Sustainability

The projects also reflect the company's disciplined approach to advancing its core businesses and growth platforms during the Rejuvenate phase of #FutureFresenius, Fresenius' transformation and growth strategy. By directing capital toward manufacturing expansion, innovation, and operational excellence, Fresenius is enhancing its long-term competitiveness.

The projects complement Fresenius' broader European investment plan, including a €400 million financing agreement signed with the European Investment Bank (EIB) in 2025 to support research and development activities as well as manufacturing expansion within the European Union.

As part of #FutureFresenius, the company will continue investing in the long-term growth and competitiveness of its businesses across (Bio)Pharma, Nutrition, and MedTech, helping improve supply chain security and access to essential medicines and healthcare products for patients around the world.

About Fresenius

Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany. In the full-year 2025, Fresenius generated €22.6 billion (excluding special items) in annual revenue. Fresenius employs more than 178,000 people. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in the separately listed Fresenius Medical Care AG. With around 140 hospitals, 330 outpatient facilities and 300 occupational risk prevention centres, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 27 million patients every year. Fresenius Kabi's product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people's health. The largest shareholder is the non-profit Else Kröner Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information, visit fresenius.com and follow Fresenius Investor Relations on LinkedIn.

About Fresenius Medical Care

Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment of approximately 25%; Fresenius Medical Care's results are not consolidated in the Fresenius Group's revenue and earnings.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Correspondence Address

Fresenius SE & Co. KGaA	Fresenius Management SE
Registered Office	**Registered Office**
Bad Homburg, Germany	Bad Homburg, Germany
Commercial Register	**Commercial Register**
Amtsgericht Bad Homburg, HRB 11852	Amtsgericht Bad Homburg, HRB 11673
Chairman of the Supervisory Board	**Management Board**
Wolfgang Kirsch	Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu
	Chairman of the Supervisory Board
	Wolfgang Kirsch

Securities Information

Fresenius SE & Co. KGaA is listed on the Frankfurt Stock Exchange and is a member of the DAX 40 index. The shares are traded on Xetra, the electronic trading venue of Deutsche Börse, under the ticker FRE.

ISIN: DE000FRE5EN2 ● German Securities Code: FRE5EN

American Depository Receipts

Fresenius SE & Co. KGaA maintains a sponsored Level I American Depositary Receipt programme, traded over the counter in the United States on the OTC Markets platform under the ticker FSNUY, at a ratio of four American Depositary Receipts to one ordinary share. Depositary bank: J.P. Morgan Chase Bank N.A.

ISIN: US35804M1053 ● CUSIP: 35804M105

Contacts

For Media contacts, click here, and to contact Investor Relations, click here.

●●● **End** ●●●